Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study — Paolo Cravedi (2011) | RDL Network
Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study
Article 2011 en
Authors
PC
Paolo Cravedi
MS
Maria Chiara Sghirlanzoni
MM
Maddalena Marasà
Abstract
1 min read
Rituximab reduced proteinuria in IMN patients with no or only transient response to unselective immunosuppression as effectively and safely as in patients without previous immunosuppression.
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.